Clinical trials: Pneumococcal Infections, open to volunteers
Pneumococcal Disease, Pneumococcal Carriage
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes just under four million serious infections every year. It is normal for pneumococcus bacteria to live in the noses of healthy adults and children as part of the…
- Trial name
- RATIONALE-15 (NCT06731374)
- Testing
- PCV15, Streptococcus pneumoniae serotype 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Acute Febrile Illness, Pneumococcal Infections
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality.
- Trial name
- PREV-HOSPIT (NCT06822907)
- Testing
- Early intervention, Delayed intervention
- Where
- 24 sites in France
- Volunteers
- 1,052 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Influenza and Pneumonia
Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients
This is a multicenter, open-label, blank-controlled clinical trial to evaluate the impact of influenza vaccination and pneumococcal vaccination on disease progression and medical burden in COPD patients aged 45-80 years, as well…
- Trial name
- NCT07640841
- Testing
- Influenza Vaccine Group, Pneumococcal Vaccine Group
- Volunteers
- 7,000 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Meningitis, Children, Only
National Bacterial Meningitis Study in Children and Newborns
Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data.
- Conditions
- Meningitis, Children, Only, Pneumococcal Conjugate Vaccine, Meningococcal Vaccines
- Trial name
- NCT04664569
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Pneumococcal Disease
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07573462
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 91 sites in United States, Argentina and 9 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Diseases
A Study to Evaluate 20vPnC in Healthy Chinese Infants
The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants.
- Trial name
- NCT07754539
- Testing
- 20vPnC, 13vPnC
- Where
- 4 sites in China
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sickle Cell Disease (SCD), Invasive Bacterial Infections
Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complications. Preventive measures, including antibiotic prophylaxis and vaccination, have changed the epidemiology of…
- Trial name
- DREPIBAC (NCT07639008)
- Where
- 31 sites in France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Disease, Invasive, Pneumococcal Disease
Serum Collection Study for Assay Development
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
- Trial name
- NCT07205289
- Testing
- Gamma-PN
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumonia, Bacterial
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
- Trial name
- NCT07406347
- Testing
- Pn-MAPS30plus, PCV20
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Pneumonia, Meningitis
Lebanese Interhospital Pneumococcal Surveillance Program
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection.
- Conditions
- Pneumonia, Meningitis, Sepsis, Bacteremia
- Trial name
- LIPSP (NCT00901602)
- Where
- Lebanon
- Volunteers
- 700 people
- Sponsor
- American University of Beirut Medical Center
Pneumonia, Pneumonia - Bacterial
Urine Pneumococcal Antigen Project
Background: Pneumonia caused by the bacteria Streptococcus pneumoniae is a leading cause of death among children under five years of age, especially in sub-Saharan Africa.
- Trial name
- UPAP (NCT07181200)
- Where
- Malawi
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Pneumonia, Pleural Effusion
Pneumonia and Pleuropneumonia in Hospitalized Children
Describe the epidemiology of hospitalized pediatric pneumonia and pleuropneumonia with pleural effusion: frequency, clinical and biological characteristics, responsible bacteria and pneumococcus place, antibiotic resistance…
- Trial name
- NCT05274607
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Pneumococcal Vaccines, Pneumococcal Infections
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
The goal of this clinical trial is to evaluate the immunogenicity and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine…
- Trial name
- NCT06608199
- Testing
- pneumococcal disease prevention
- Where
- 3 sites in Indonesia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)
The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection.
- Conditions
- Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection, Influenza Infection
- Trial name
- NoseSpnElderly (NCT06998251)
- Where
- Switzerland
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Pneumococcal Infection
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae.
- Trial name
- NCT07300267
- Testing
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1)
- Where
- 15 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC